Also known as P021 · P-21 · CNTF-derived peptide
A CNTF-derived peptidergic compound with an adamantane group, studied as a neurogenic, BDNF-enhancing agent in Alzheimer’s models.
Research refreshed
P21 (also written P021) is a small peptidergic compound derived from a biologically active region of ciliary neurotrophic factor (CNTF), modified with an adamantane moiety to improve stability and brain penetration. It is studied for enhancing neurogenesis and BDNF signaling and for reducing tau pathology in preclinical Alzheimer’s-disease and neurodegeneration models. It is a research compound with no clinical data and no approval.
P021 came from efforts to capture the neurotrophic activity of ciliary neurotrophic factor in a small, stable molecule. By taking an active CNTF-derived peptide and attaching an adamantane group, researchers aimed for a compound that resists breakdown and reaches the brain while promoting new neuron formation and BDNF expression.
In transgenic and aging rodent models it has been reported to increase neurogenesis, raise BDNF, and lower tau pathology and cognitive deficits. This is preclinical neuroscience research; there is no clinical trial, no human data, and no approval. This page is a research and educational reference.
Derived from a CNTF peptide region; reported to antagonize the neurogenesis-inhibitor pathway and increase BDNF and neurotrophic signaling, with downstream reductions in tau hyperphosphorylation in animal models. The adamantane modification supports metabolic stability and CNS exposure.
Behind every vial of P21 (P021) is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how P21 (P021), specifically, is brought into being.
P21 (P021) begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
P21 (P021) is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — P21 (P021) plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of P21 (P021) proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of P21 (P021) — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
A small peptidergic compound derived from ciliary neurotrophic factor and modified with an adamantane group. Synthesis couples a short peptide to the adamantane moiety, and the identity-critical step is confirming that conjugation — a certificate that characterizes only the peptide portion does not establish that the adamantane-bearing active compound was actually made.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning P021, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
A CNTF-derived peptidergic compound with an adamantane group, studied for enhancing neurogenesis and BDNF signaling and reducing tau pathology in preclinical Alzheimer’s models.
Neurogenesis, BDNF/neurotrophic signaling, and reduction of tau pathology and cognitive deficits in rodent models of neurodegeneration.
No — the published work is in animal models. There is no clinical trial or human safety data.
No. This page is a research and educational reference, not medical advice.
Synthetic Glu-Asp-Arg tripeptide studied as a brain/CNS bioregulator.
ViewA natural brain / CNS peptide complex (Cytomax A-1) — the extract-based counterpart to Pinealon, targeting neuronal tissue.
ViewRussian synthetic ACTH(4-10) analog studied for nootropic and neuroprotective effects.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.